What’s really happening in the Cipla–Pfizer tie‑up
At first glance, the announcement looks modest: Cipla gets exclusive rights to market and distribute five established Pfizer brands—Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C—for five years in India, while Pfizer continues to manufacture and supply. There is no upfront payment disclosed; commercial terms are kept confidential, and Pfizer simultaneously signals a reduction in its India field force tied to this transition.[2][1]
Behind those dry bullets lies a clear message:
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
